Thematics Asset Management Sells 8,938 Shares of Natera, Inc. (NASDAQ:NTRA)

Thematics Asset Management lessened its stake in Natera, Inc. (NASDAQ:NTRA) by 12.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 64,554 shares of the medical research company’s stock after selling 8,938 shares during the period. Thematics Asset Management’s holdings in Natera were worth $8,195,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Itau Unibanco Holding S.A. bought a new position in Natera during the 2nd quarter worth approximately $28,000. Quarry LP boosted its position in shares of Natera by 148.4% during the 2nd quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 190 shares in the last quarter. GAMMA Investing LLC grew its stake in Natera by 50.0% during the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock worth $35,000 after purchasing an additional 108 shares during the period. Covestor Ltd lifted its position in shares of Natera by 34.3% during the 3rd quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 95 shares during the period. Finally, Brooklyn Investment Group bought a new position in Natera during the third quarter worth $70,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Natera Stock Up 0.6 %

Natera stock traded up $0.95 during midday trading on Tuesday, hitting $165.34. 137,829 shares of the stock were exchanged, compared to its average volume of 1,345,407. Natera, Inc. has a 52-week low of $53.88 and a 52-week high of $171.95. The company has a quick ratio of 4.23, a current ratio of 4.39 and a debt-to-equity ratio of 0.33. The business’s 50-day moving average price is $131.54 and its 200-day moving average price is $118.15. The stock has a market capitalization of $21.83 billion, a price-to-earnings ratio of -93.40 and a beta of 1.53.

Natera (NASDAQ:NTRA) last announced its earnings results on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. The firm had revenue of $439.80 million for the quarter, compared to the consensus estimate of $361.43 million. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The company’s revenue was up 63.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.95) EPS. On average, research analysts expect that Natera, Inc. will post -1.66 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on NTRA shares. TD Cowen lifted their price target on shares of Natera from $155.00 to $175.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Leerink Partners boosted their target price on Natera from $140.00 to $150.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. JPMorgan Chase & Co. increased their price target on Natera from $135.00 to $160.00 and gave the stock an “overweight” rating in a report on Wednesday, November 13th. Craig Hallum raised their price objective on Natera from $121.00 to $157.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, Robert W. Baird upped their target price on Natera from $120.00 to $160.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. One analyst has rated the stock with a sell rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $140.59.

Insider Buying and Selling at Natera

In other Natera news, CEO Steven Leonard Chapman sold 5,024 shares of the business’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $128.48, for a total value of $645,483.52. Following the transaction, the chief executive officer now directly owns 195,686 shares in the company, valued at $25,141,737.28. The trade was a 2.50 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gail Boxer Marcus sold 9,682 shares of Natera stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $159.98, for a total transaction of $1,548,926.36. Following the completion of the sale, the director now directly owns 9,704 shares in the company, valued at $1,552,445.92. This trade represents a 49.94 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 46,503 shares of company stock worth $6,325,804 in the last quarter. 7.60% of the stock is currently owned by company insiders.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.